← Back
Aardvark Therapeutics
AARD · listed on Nasdaq · worth $31.95 million
$1.51
+16.15% on Oct 28
Two insider buys in the last year, $144.6K in all. None in the last two weeks.
Green dot = an insider bought red = sold◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
11.0M shares
50% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders bought Aardvark Therapeutics stock and one insider sold. Every one of the 2 sales is marked on its filing as planned in advance; all by company executives.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Executive Officer
Tien-Li Lee
Bought $101.4K on Dec 11, 2025 — 7,000 shares at $14.49, 0.5% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Chief Financial Officer
Nelson Sun
Bought $43.2K on Dec 11, 2025 — 3,000 shares at $14.40, 2.8% of what they now own.
0 of 1 earlier purchase did better than the S&P 500
Planned sales
Form 144 notices filed for Aardvark Therapeutics in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Nelson Sun filed to sell 33,911 shares on 11 Sep; sold 76,754 by 11 Sep, more than the notice named10b5-1 plan adopted 11 Jun 2026 · Notice on SEC.gov
Nelson Sun filed to sell 42,843 shares on 10 Sep; no sale reported yet10b5-1 plan adopted 11 Jun 2026 · Notice on SEC.gov
All reports
Every insider trade and SEC report we hold for Aardvark Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 11SoldNelson SunSep 11 · See Remarks · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.62,000 @ $5.18$321.2K
Sep 11SoldNelson SunSep 11 · Traded Sep 10 · See Remarks · A trade scheduled ahead of time under a written plan, so its timing was set before the day it happened.14,754 @ $5.00$73.8K
Dec 12, 2025BoughtNelson SunDec 12, 2025 · Traded Dec 11, 2025 · Chief Financial Officer+2.8%3,000 @ $14.40$43.2K
Dec 12, 2025BoughtTien-Li Lee10%Dec 12, 2025 · Traded Dec 11, 2025 · Chief Executive Officer+0.5%7,000 @ $14.49$101.4K
Sep 16, 2025BoughtTien-Li Lee10%Sep 16, 2025 · Traded Sep 15, 2025 · Chief Executive Officer+0.2%3,500 @ $9.94$34.8K
5 more with Pro →Analysts, earnings and news
Analysts' price target
$15.44 average
9 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26−$0.66 a share+$0.22
Q1 '26−$0.99 a share−$0.08
Q4 '25−$0.81 a share+$0.02
Q3 '25−$0.75 a share+$0.05